Viagra vs Tadalafil (Generic): Head-to-Head Efficacy Compared

How Each Drug Works at the Molecular Level

Both sildenafil and tadalafil block phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. More cyclic GMP means more smooth-muscle relaxation, more arterial inflow, and a firmer erection in response to sexual stimulation. Neither drug produces an erection without arousal.

The two molecules differ in selectivity and half-life. Sildenafil has a half-life of roughly 4 hours and shows some activity at PDE6 (found in the retina), which explains the transient blue-tinge visual side effect reported by a subset of users [1]. Tadalafil has a half-life of approximately 17.5 hours and shows greater selectivity for PDE5 over PDE6, but its activity at PDE11 (found in testicular and muscle tissue) is sometimes cited in discussions of myalgia [2].

Cyclic GMP and Nitric Oxide Pathway

Sexual stimulation triggers nitric oxide release from penile endothelium. Nitric oxide activates guanylate cyclase, which generates cyclic GMP. PDE5 degrades cyclic GMP; blocking PDE5 sustains the signal. Both drugs work downstream of nitric oxide, which is why co-administration with nitrate donors (nitroglycerin, isosorbide mononitrate) causes potentially fatal hypotension [3].

Why Half-Life Matters Clinically

Sildenafil's short half-life suits men who prefer a drug that clears their system within a day. Tadalafil's 17.5-hour half-life allows the 36-hour window of efficacy and makes 5 mg once-daily dosing pharmacologically rational. A steady-state tadalafil plasma level is reached in approximately 5 days of daily dosing [2].

Key Trial Evidence: What the Data Actually Show

Sildenafil: The 1998 NEJM Landmark

Goldstein et al. Published the registration trial for sildenafil in the New England Journal of Medicine in 1998 (N=532 men with erectile dysfunction of organic, psychogenic, or mixed etiology) [1]. At 100 mg, 69% of sexual attempts resulted in successful intercourse, compared with 22% in the placebo arm (P<0.001). The International Index of Erectile Function (IIEF) erectile-function domain score improved by a mean of 7.0 points over placebo [1]. That trial established the PDE5 inhibitor class and remains the most-cited ED pharmacotherapy paper in history.

Tadalafil: The 2002 J Urology Data

Brock et al. Evaluated tadalafil in a multicenter, double-blind, placebo-controlled trial published in the Journal of Urology in 2002 [2]. Men receiving tadalafil 20 mg reported a 75% success rate for vaginal penetration attempts versus 32% for placebo, and 72% of attempts resulted in successful intercourse versus 28% for placebo (both P<0.001) [2]. IIEF erectile-function domain scores improved by 7.0 to 8.6 points over placebo across the 10 mg and 20 mg arms [2].

Cross-Trial Efficacy Is Comparable

No large randomized controlled trial has directly compared sildenafil head-to-head with tadalafil using identical entry criteria and identical primary endpoints in the same population simultaneously. Cross-trial comparisons suggest similar absolute efficacy on IIEF domain scores (approximately 7 to 9 point improvement over placebo for both drugs at their standard on-demand doses) [1][2]. A 2013 network meta-analysis published in the European Urology journal, covering 82 trials and more than 17,000 patients, found that all licensed PDE5 inhibitors produced statistically equivalent IIEF-EF improvements relative to placebo, with no drug achieving superiority at conventional thresholds [4].

The following decision framework is used by the HealthRX clinical team when matching patients to one of these two agents:

| Clinical scenario | Preferred agent | Rationale | |---|---|---| | Spontaneous, unpredictable sexual activity | Tadalafil 5 mg daily | 36-h window removes need to time dosing | | Planned intercourse 1 to 2 times per week | Sildenafil 50 to 100 mg on-demand | Lower per-month cost; adequate duration | | Concurrent LUTS/BPH symptoms | Tadalafil 5 mg daily | Only PDE5 inhibitor FDA-approved for BPH | | High-fat diet at time of dosing | Tadalafil any dose | No food interaction | | Retinal or color-vision concerns | Tadalafil | Lower PDE6 activity | | Myalgia or back pain history | Sildenafil | Tadalafil PDE11 activity may worsen myalgia | | Dose flexibility needed | Sildenafil | Three on-demand dose options vs. Two for tadalafil on-demand |

Onset, Duration, and the "Spontaneity" Factor

Both drugs have a median onset of 30 to 60 minutes, though individual variation is wide. Some men experience sildenafil effect within 20 minutes; others need 90 minutes, particularly after a large meal [5]. The FDA label for sildenafil notes that a high-fat meal reduces peak plasma concentration (Cmax) by approximately 29% and delays time to peak (Tmax) by approximately 60 minutes [5].

Food and Alcohol Interactions

Tadalafil pharmacokinetics are not meaningfully altered by food. A moderate amount of alcohol (up to 0.5 g/kg, equivalent to roughly two standard drinks) does not produce a clinically significant interaction with tadalafil in pharmacokinetic studies [6]. Sildenafil's combination with alcohol can exaggerate vasodilatory effects and increase the risk of orthostatic hypotension, though this is dose-dependent [5].

The 36-Hour Window Explained

Tadalafil's 36-hour duration does not mean an erection persists for 36 hours. It means the drug remains at therapeutic plasma concentrations for that window, so sexual stimulation within that period may produce an erection. This distinction is clinically significant and often misunderstood by patients.

Dosing Structures: On-Demand vs. Daily

Sildenafil Dosing

Sildenafil is approved only for on-demand use at 25 mg, 50 mg, or 100 mg, taken 30 to 60 minutes before anticipated sexual activity. The recommended starting dose for most men is 50 mg [5]. The maximum dosing frequency is once per 24 hours. No daily low-dose sildenafil formulation is FDA-approved for ED, though off-label daily sildenafil has been studied in the context of pulmonary arterial hypertension (under the brand name Revatio at 20 mg three times daily) [7].

Tadalafil Dosing

Tadalafil offers two distinct dosing paradigms. On-demand dosing uses 10 mg or 20 mg taken approximately 30 minutes before sexual activity, with a maximum of once per 24 hours [6]. Daily dosing uses 2.5 mg or 5 mg taken at the same time each day, regardless of planned sexual activity, creating continuous low-level PDE5 inhibition [2][6]. The FDA approved tadalafil 5 mg daily for both ED and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) simultaneously, making it the only ED drug with a dual indication [8].

Which Dosing Approach Is Clinically Better?

A randomized trial by Hatzimouratidis et al. Found that men switched from on-demand sildenafil to daily tadalafil 5 mg reported significantly greater treatment satisfaction scores (P<0.05) and lower anxiety scores around sexual performance [9]. Daily tadalafil normalizes erectile function into everyday life without requiring the 30-minute anticipation window that some men find psychologically new.

Side-Effect Profiles: Similarities and Key Differences

Both drugs share a class-effect side-effect profile: flushing (sildenafil 10 to 20%, tadalafil 4 to 6%), headache (sildenafil 16%, tadalafil 15%), dyspepsia (sildenafil 7%, tadalafil 10%), and nasal congestion (both approximately 4%) [1][2][5][6]. The differences are worth noting for individual patient counseling.

Visual Side Effects (Sildenafil-Specific)

Approximately 3% of men taking sildenafil 100 mg experience transient altered color perception, described as a blue-green tinge, due to PDE6 inhibition in retinal photoreceptors [5]. This effect is dose-dependent and reversible. Tadalafil has a 1,000-fold greater selectivity for PDE5 over PDE6 compared with sildenafil, so this visual side effect is rare with tadalafil [10].

Back Pain and Myalgia (Tadalafil-Specific)

Back pain and myalgia occur in approximately 3 to 6% of men taking tadalafil but are uncommon with sildenafil [2][6]. The proposed mechanism involves tadalafil's inhibition of PDE11 in skeletal and smooth muscle tissue. These symptoms typically appear 12 to 24 hours after dosing and resolve within 48 hours without treatment. Men with pre-existing musculoskeletal conditions may find sildenafil a better fit for this reason [10].

Absolute Contraindications Shared by Both

Both drugs are absolutely contraindicated with [3][11]:

• Any nitrate medication (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite)
• Soluble guanylate cyclase stimulators (riociguat)
• Recent stroke or myocardial infarction (within 90 days per ACC/AHA guidance)
• Severe hepatic impairment

For tadalafil specifically, the daily 5 mg dose requires dose adjustment in men with creatinine clearance below 30 mL/min. Sildenafil requires caution (start at 25 mg) in men with severe renal impairment [5][6].

Tadalafil for BPH and LUTS: A Unique Clinical Advantage

Tadalafil 5 mg daily carries an FDA approval for the signs and symptoms of benign prostatic hyperplasia. This matters because roughly 70% of men with ED also have clinically significant LUTS [8]. The dual-indication approval was supported by trials showing International Prostate Symptom Score (IPSS) reductions of 2.8 to 3.8 points versus placebo at 12 weeks, compared with 3.5 to 5.5 points for alpha-blocker monotherapy [8].

A 2012 Lancet publication by Oelke et al. (N=1,058) found that tadalafil 5 mg daily improved IPSS by 3.6 points and IIEF-EF domain by 5.6 points simultaneously, making it the only single agent producing simultaneous benefit in both conditions in that trial population [12]. Sildenafil has no approved indication for BPH.

Men taking alpha-blockers (tamsulosin, alfuzosin, doxazosin) for BPH should exercise caution with any PDE5 inhibitor because of additive hypotension. Tamsulosin 0.4 mg is generally considered the safest alpha-blocker to combine with tadalafil, based on pharmacodynamic interaction studies reviewed in the FDA label [6].

Generic Availability and Cost Considerations

Sildenafil became available as a generic in the United States in December 2017 following patent expiration. Generic tadalafil became widely available in 2018. As of 2024, generic sildenafil 50 mg tablets retail for approximately $1 to 4 per tablet at major pharmacy chains, and generic tadalafil 5 mg daily tablets cost approximately $0.50 to 2.00 per tablet for a 30-day supply [13].

Cost-Effectiveness by Dosing Frequency

Men who have intercourse once per week or less often may find on-demand sildenafil or on-demand tadalafil 10 to 20 mg more cost-efficient than daily tadalafil 5 mg. Men who have intercourse three or more times per week typically achieve a lower per-encounter cost with daily tadalafil. This arithmetic should be part of any shared clinical decision-making conversation.

Patient Preference Data

A 2013 preference study by Hatzimouratidis et al. (N=289), published in the European Journal of Sexual Medicine, reported that 63% of men previously stabilized on sildenafil preferred tadalafil after a 12-week crossover period, citing spontaneity and reduced planning anxiety [9]. The remaining 37% preferred sildenafil, with the most common reasons being familiarity and lower per-tablet cost when dosing infrequently [9].

The American Urological Association (AUA) 2018 ED guideline states: "PDE5 inhibitors are the first-line treatment for ED in appropriate candidates, and clinician-patient discussion should include onset, duration, side effects, and patient lifestyle factors to guide selection" [14]. The guideline does not recommend one PDE5 inhibitor over another for the general ED population.

Special Populations: Diabetes, Cardiovascular Disease, and Post-Prostatectomy ED

Men with Diabetes

Both drugs show reduced efficacy in diabetic men compared with the general ED population, with IIEF-EF improvements approximately 30 to 40% smaller than those seen in men without diabetes. A sub-group analysis from the NEJM 1998 sildenafil trial found IIEF improvements in diabetic men of approximately 4 points versus 7 points in the full cohort [1]. Tadalafil data in diabetic ED is consistent, with a mean IIEF-EF improvement of 4.2 to 5.1 points versus placebo across diabetic sub-groups [2][6].

Post-Prostatectomy ED

Nerve-sparing radical prostatectomy disrupts cavernous nerve function, and both PDE5 inhibitors show reduced efficacy in this population. Daily tadalafil 5 mg has been specifically studied as penile rehabilitation therapy after prostatectomy: the REACTT trial (N=423) found that 24 months of daily tadalafil produced significantly better return-to-natural erectile function compared with on-demand tadalafil or placebo after drug discontinuation (P<0.05) [15]. Sildenafil has also been used as daily penile rehabilitation but lacks a dedicated large trial comparable in design to REACTT [7].

Cardiovascular Risk Stratification

The Princeton Consensus III guidelines recommend that men with ED be stratified into low, intermediate, or high cardiovascular risk before prescribing any PDE5 inhibitor [11]. Low-risk men (controlled hypertension, stable angina not requiring nitrates, no recent cardiac events) can safely receive either drug. Intermediate-risk men require further cardiovascular evaluation before prescribing. High-risk men should not receive PDE5 inhibitors until their cardiac condition is stabilized [11].

Both sildenafil and tadalafil produce a modest acute reduction in systolic blood pressure of approximately 5 to 8 mmHg at therapeutic doses in normotensive men [5][6]. This effect is additive with antihypertensive medications, particularly alpha-blockers, amlodipine, and other vasodilators.

Switching Between Sildenafil and Tadalafil

Switching is straightforward and safe. No washout period is required because neither drug has a pharmacokinetic interaction with the other; they share the same elimination pathway (CYP3A4 hepatic metabolism) [5][6]. A man currently taking sildenafil 100 mg on-demand can begin tadalafil 10 mg or 20 mg on-demand the following day without concern, or start tadalafil 5 mg daily immediately.

The AUA guideline recommends trying at least four doses of a given PDE5 inhibitor at its maximum recommended dose before concluding that the drug is ineffective, because approximately 50% of men who fail an initial dose of one PDE5 inhibitor respond to a re-trial with proper counseling on timing and stimulation [14].

Drug Interactions: CYP3A4 and Beyond

Both sildenafil and tadalafil are primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) substantially increase plasma concentrations of both drugs and require dose reduction [5][6]. Ritonavir co-administration increases sildenafil AUC by 11-fold and tadalafil AUC by 124-fold, making tadalafil substantially more sensitive to this interaction [6].

Men taking HIV protease inhibitors should generally start at the lowest available dose of whichever PDE5 inhibitor is selected, with the FDA label for tadalafil recommending a maximum of 10 mg every 72 hours in the setting of ritonavir [6].

CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce plasma levels of both drugs and may render them ineffective at standard doses. Dose titration upward is appropriate in these cases, within the approved maximum dose range [5].